Join

Compare · AKUS vs VOR

AKUS vs VOR

Side-by-side comparison of Akouos Inc. (AKUS) and Vor Biopharma Inc. (VOR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • AKUS operates in Consumer Discretionary, while VOR operates in Health Care - the two are in different parts of the market.
  • VOR is the larger of the two at $778.1M, about 4.0x AKUS ($197.0M).
  • VOR has hit the wire 14 times in the past 4 weeks while AKUS has been quiet.
  • VOR has more recent analyst coverage (16 ratings vs 1 for AKUS).
MetricAKUSVOR
Company
Akouos Inc.
Vor Biopharma Inc.
Price
$13.29+1.10%
$14.37+2.10%
Market cap
$197.0M
$778.1M
1M return
-
-9.71%
1Y return
-
+294.56%
Sector
Consumer Discretionary
Health Care
Industry
Specialty Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2020
2021
News (4w)
0
14
Recent ratings
1
16
AKUS

Akouos Inc.

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

VOR

Vor Biopharma Inc.

Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest AKUS

Latest VOR